Literature DB >> 21762328

Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia.

Asha Pillai1, Christine Hartford, Chong Wang, Deqing Pei, Jie Yang, Ashok Srinivasan, Brandon Triplett, Mari Dallas, Wing Leung.   

Abstract

To assess whether a tolerance-induction regimen could be applied for unrelated (MUD) HCT in SAA, we retrospectively reviewed our HCT experience using unmanipulated 10/10 HLA-matched bone marrow grafts from MSD vs. MUD donors. Conditioning was CTX 200 mg/kg (CTX) + rabbit ATG 10 mg/kg (ATG) for MSD (n = 9) and TLI (800 cGy) + CTX/ATG for MUD HCT ( n = 5). Immunoprophylaxis was CSA and short-course MTX. Median patient age was 14.7 yr, median time to HCT 1.5 yr, and median follow-up 3 yr. Outcome measures included EFS, time to engraftment, and cumulative incidence of GVHD (CIN of GVHD) for MSD and MUD cohorts. EFS and stable engraftment rate were 100%. CIN of acute GVHD was: MSD, Grade I-II: 1 (11%), Grade III-IV: 0%; MUD, Grade I-II: 1 (20%), Grade III-IV: 1 (20%). CIN of chronic GVHD was: MSD, limited: 1 (11%), extensive: 0%; MUD, limited: 0%, extensive: 0%. All immunosuppressive-compliant patients successfully weaned immunosuppression. Although in limited patients, our results suggest that immunomodulatory TLI added to backbone CTX/ATG conditioning is a promising option for MUD HCT in SAA patients, which we will examine in a prospective clinical trial.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21762328      PMCID: PMC3538876          DOI: 10.1111/j.1399-3046.2011.01542.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  42 in total

Review 1.  The modern management of severe aplastic anaemia.

Authors:  S E Ball
Journal:  Br J Haematol       Date:  2000-07       Impact factor: 6.998

Review 2.  Effector and regulatory lymphoid cells and cytokines in mucosal sites.

Authors:  T T MacDonald
Journal:  Curr Top Microbiol Immunol       Date:  1999       Impact factor: 4.291

Review 3.  The pathophysiology of acquired aplastic anemia.

Authors:  N S Young; J Maciejewski
Journal:  N Engl J Med       Date:  1997-05-08       Impact factor: 91.245

4.  Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia.

Authors:  H J Kang; H Y Shin; H S Choi; H S Ahn
Journal:  Bone Marrow Transplant       Date:  2004-12       Impact factor: 5.483

5.  Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia.

Authors:  S J Rosenfeld; J Kimball; D Vining; N S Young
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

Review 6.  Chronic graft-versus-host disease.

Authors:  Stephanie J Lee; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2003-04       Impact factor: 5.742

7.  Transcript profile of CD4+ and CD8+ T cells from the bone marrow of acquired aplastic anemia patients.

Authors:  Weihua Zeng; Sachiko Kajigaya; Guibin Chen; Antonio M Risitano; Olga Nunez; Neal S Young
Journal:  Exp Hematol       Date:  2004-09       Impact factor: 3.084

8.  Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease.

Authors:  W Krenger; K M Snyder; J C Byon; G Falzarano; J L Ferrara
Journal:  J Immunol       Date:  1995-07-15       Impact factor: 5.422

9.  Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program.

Authors:  N A Kernan; G Bartsch; R C Ash; P G Beatty; R Champlin; A Filipovich; J Gajewski; J A Hansen; J Henslee-Downey; J McCullough
Journal:  N Engl J Med       Date:  1993-03-04       Impact factor: 91.245

10.  Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results.

Authors:  R E Champlin; M M Horowitz; D W van Bekkum; B M Camitta; G E Elfenbein; R P Gale; E Gluckman; R A Good; A A Rimm; C Rozman
Journal:  Blood       Date:  1989-02       Impact factor: 22.113

View more
  5 in total

1.  Recipient myeloid-derived immunomodulatory cells induce PD-1 ligand-dependent donor CD4+Foxp3+ regulatory T cell proliferation and donor-recipient immune tolerance after murine nonmyeloablative bone marrow transplantation.

Authors:  Marie van der Merwe; Hossam A Abdelsamed; Aman Seth; Taren Ong; Peter Vogel; Asha B Pillai
Journal:  J Immunol       Date:  2013-11-04       Impact factor: 5.422

2.  Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia.

Authors:  Zhi Guo; Hong-Yan Gao; Tian-Yan Zhang; Xiao-Dong Liu; Kai Yang; Jing-Xing Lou; Xue-Peng He; Yuan Zhang; Peng Chen; Hui-Ren Chen
Journal:  Int J Hematol       Date:  2016-10-05       Impact factor: 2.490

3.  Bidirectional immune tolerance in nonmyeloablative MHC-mismatched BMT for murine β-thalassemia.

Authors:  Shuyu E; Aman Seth; Peter Vogel; Matt Sommers; Taren Ong; Asha B Pillai
Journal:  Blood       Date:  2017-03-28       Impact factor: 22.113

4.  TLI in pediatric patients.

Authors:  A Ocanto; A Escribano; L Glaría; I Rodríguez; C Ferrer; C Huertas; A Pérez; R Morera
Journal:  Clin Transl Oncol       Date:  2019-09-21       Impact factor: 3.405

Review 5.  Regulatory immunotherapy in bone marrow transplantation.

Authors:  Vanessa Morales-Tirado; Wioleta Luszczek; Marié van der Merwe; Asha Pillai
Journal:  ScientificWorldJournal       Date:  2012-01-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.